Sibelius has completed a final report on the Mechanism of Action (MOA) of an active anti-ageing compound from a world leading cosmeceutical company.

The ChronoscreenTM has been successfully used for the first time for analysis of the compound’s MOA in C. elegans. Using RNAi knockdown and the high through-put, phenotypic screening technology of the ChronoscreenTM, Sibelius has been able to determine pathways involved in the activity of this anti-ageing compound. 

Share this post: